Cardinal Health elects David Anderson to board
DUBLIN, OH — Cardinal Health on Monday announced that its board of directors elected David J. Anderson as an independent director. Anderson most recently served as SVP and CFO of Honeywell International. He also will serve on the board’s audit committee.
"We are extremely pleased to welcome Dave to our board of directors," said George Barrett, chairman and CEO of Cardinal Health. "Dave has a distinguished career across multiple industries and is recognized by investors and peers as one of America’s top CFOs. With close to two decades of experience with high-performing public companies, we know his contributions will be invaluable."
Anderson currently sits on the board of directors of American Electric Power. He is a graduate of Indiana University and also received an MBA from the University of Chicago’s Booth School of Business.
Mylan challenges FDA ruling on celecoxib
PITTSBURGH — Mylan last week announced that it filed suit against the Food and Drug Administration, challenging the agency’s decision regarding generic drug marketing exclusivity on celecoxib capsules, the generic equivalent of Pfizer’s Celebrex.
Mylan believes that the agency was misguided in its decision in the case and maintains that it is in a position to receive final approval on May 30 when Celebrex’s remaining patents expire. Other companies have settled for a December 2014 launch date and will be unable to launch on May 30.
"We believe the FDA has made an unprecedented error in this case which clearly caught all industry participants off guard, as evidenced by some who have already settled with Pfizer for December 2014 launch dates, which is post patent expiry. Mylan seeks an order compelling FDA to grant final approval of Mylan’s ANDA on May 30, 2014," said Heather Bresch, Mylan CEO.
Sandoz announces generic Differin gel
PRINCETON, N.J. — Sandoz on Monday announced the introduction of its adapalene 0.3% gel, a generic version of Differin gel, 0.3% from Galderma Labs. Adapalene gel is a retinoid and is used for the topical treatment of acne vulgaris in patients ages 12 years and older.
"Sandoz is proud to market a high-quality, affordable generic version of this important topical therapy,” said Peter Goldschmidt, president of Sandoz U.S. “This launch further broadens our strong offering of differentiated generic dermatology products in the United States.”
Sandoz will market the gel through a collaboration with Tolmar Inc., which owns the abbreviated new drug application for the product and was the first company to receive FDA approval for a generic equivalent.
Sandoz will market the adapalene 0.3% gel in 45 gram tubes. U.S. sales for Differin gel 0.3% in 45-g tubes was approximately $87 million for the 12 months ending December 2013, according to IMS Health.